Brean Capital Initiates Akebia Therapeutics At Buy

Analysts at Brean Capital initiated coverage on

with a Buy rating. The target price for Akebia Therapeutics is set to $18. Akebia Therapeutics shares have dropped 64.17 percent over the past 52 weeks, while the S&P 500 index has surged 11.12 percent in the same period. Akebia Therapeutics' shares fell 1.28 percent to close at $7.71 yesterday.